This was the stock's fifth consecutive day of gains.

Regeneron Pharmaceuticals (Nasdaq: REGN) today announced that the European Commission (EC) has granted conditional marketing ...

Regeneron Pharmaceuticals has received a total of 10 ratings from analysts, with the consensus rating as Buy. With an average one-year price target of $797.9, the consensus suggests a potential 32.4% ...

Approval of Lynozyfic is based on data showing deep and durable responses in relapsed/refractory multiple myeloma Lynozyfic will provide a new option with convenient dosing and administration to patie ...

ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced ...

(NASDAQ: REGN) today announced that the European Commission (EC) has granted conditional marketing approval of Lynozyfic™ (linvoseltamab) to treat adults with relapsed and refractory (R/R) multiple ...

Biotech company Regeneron (NASDAQ:REGN) will be reporting earnings tomorrow morning. Here’s what you need to know.

As April gives way to May, the market braces for a blockbuster week packed with earnings from some of the biggest names ...

With that in mind, let's consider two stocks down 17% and 36%, respectively, this year that are worth investing in right now: Regeneron Pharmaceuticals ( REGN 0.40%) and Moderna ( MRNA -0.79%).

Baird lowered the firm’s price target on Regeneron (REGN) to $652 from $759 and keeps a Neutral rating on the shares. The firm said its Eylea ...

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and ...

Sanofi (SNY) stock and Roche (RHHBY) stock trade flat after the duo reaffirmed 2025 forecasts despite strong Q1 results. Read ...